A nomogram model combining ultrasound-based radiomics features and clinicopathological factors to identify germline BRCA1/2 mutation in invasive breast cancer patients

被引:3
作者
Guo, Ruohan [1 ]
Yu, Yiwen [1 ]
Huang, Yini [1 ]
Lin, Min [1 ]
Liao, Ying [1 ]
Hu, Yixin [1 ]
Li, Qing [1 ]
Peng, Chuan [1 ]
Zhou, Jianhua [1 ]
机构
[1] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Ultrasound, Canc Ctr,State Key Lab Oncol South China, 651 Dongfeng Rd East, Guangzhou 510060, Peoples R China
关键词
BRCA mutation; Invasive breast cancer; Ultrasound; Radiomics; Nomogram; IMAGING FEATURES; CARCINOMA; ESTROGEN; CRITERIA; GENES; WOMEN; RISK;
D O I
10.1016/j.heliyon.2023.e23383
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objective: BRCA1/2 status is a key to personalized therapy for invasive breast cancer patients. This study aimed to explore the association between ultrasound radiomics features and germline BRCA1/2 mutation in patients with invasive breast cancer.Materials and methods: In this retrospective study, 100 lesions in 92 BRCA1/2-mutated patients and 390 lesions in 357 non-BRCA1/2-mutated patients were included and randomly assigned as training and validation datasets in a ratio of 7:3. Gray-scale ultrasound images of the largest plane of the lesions were used for feature extraction. Maximum relevance minimum redundancy (mRMR) algorithm and multivariate logistic least absolute shrinkage and selection operator (LASSO) regression were used to select features. The multivariate logistic regression method was used to construct predictive models based on clinicopathological factors, radiomics features, or a combination of them.Results: In the clinical model, age at first diagnosis, family history of BRCA1/2-related malignancies, HER2 status, and Ki-67 level were found to be independent predictors for BRCA1/2 mutation. In the radiomics model, 10 significant features were selected from the 1032 radiomics features extracted from US images. The AUCs of the radiomics model were not inferior to those of the clinical model in both training dataset [0.712 (95% CI, 0.647-0.776) vs 0.768 (95% CI, 0.704-0.835); p = 0.429] and validation dataset [0.705 (95% CI, 0.597-0.808) vs 0.723 (95% CI, 0.625-0.828); p = 0.820]. The AUCs of the nomogram model combining clinical and radiomics features were 0.804 (95% CI, 0.748-0.861) in the training dataset and 0.811 (95% CI, 0.724-0.894) in the validation dataset, which were proved significantly higher than those of the clinical model alone by DeLong's test (p = 0.041; p = 0.007). To be noted, the negative predictive values (NPVs) of the nomogram model reached a favorable 0.93 in both datasets.Conclusion: This machine nomogram model combining ultrasound-based radiomics and clinical features exhibited a promising performance in identifying germline BRCA1/2 mutation in patients with invasive breast cancer and may help avoid unnecessary gene tests in clinical practice.
引用
收藏
页数:12
相关论文
共 46 条
[11]   Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 [J].
Goldhirsch, A. ;
Winer, E. P. ;
Coates, A. S. ;
Gelber, R. D. ;
Piccart-Gebhart, M. ;
Thuerlimann, B. ;
Senn, H. -J. .
ANNALS OF ONCOLOGY, 2013, 24 (09) :2206-2223
[12]   Comparison of background parenchymal enhancement and fibroglandular density at breast magnetic resonance imaging between BRCA gene mutation carriers and non-carriers [J].
Grubstein, Ahuva ;
Rapson, Yael ;
Benzaquen, Oshra ;
Rozenblatt, Shira ;
Gadiel, Itay ;
Atar, Eli ;
Yerushalmi, Rinat ;
Cohen, Matan J. .
CLINICAL IMAGING, 2018, 51 :347-351
[13]   Ultrasound radiomics in personalized breast management: Current status and future prospects [J].
Gu, Jionghui ;
Jiang, Tian'an .
FRONTIERS IN ONCOLOGY, 2022, 12
[14]   Deep learning radiomics of ultrasonography can predict response to neoadjuvant chemotherapy in breast cancer at an early stage of treatment: a prospective study [J].
Gu, Jionghui ;
Tong, Tong ;
He, Chang ;
Xu, Min ;
Yang, Xin ;
Tian, Jie ;
Jiang, Tianan ;
Wang, Kun .
EUROPEAN RADIOLOGY, 2022, 32 (03) :2099-2109
[15]   Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status [J].
Haffty, BG ;
Harrold, E ;
Khan, AJ ;
Pathare, P ;
Smith, TE ;
Turner, BC ;
Glazer, PM ;
Ward, B ;
Carter, D ;
Matloff, E ;
Bale, AE ;
Alvarez-Franco, M .
LANCET, 2002, 359 (9316) :1471-1477
[16]   Detection of BRCA1 and BRCA2 germline mutations in Japanese population using next-generation sequencing [J].
Hirotsu, Yosuke ;
Nakagomi, Hiroshi ;
Sakamoto, Ikuko ;
Amemiya, Kenji ;
Mochizuki, Hitoshi ;
Omata, Masao .
MOLECULAR GENETICS & GENOMIC MEDICINE, 2015, 3 (02) :121-129
[17]   Germline and tumor BRCA1/2 pathogenic variants in Chinese triple-negative breast carcinomas [J].
Ji, Gang ;
Bao, Longlong ;
Yao, Qianlan ;
Zhang, Jing ;
Zhu, Xiaoli ;
Bai, Qianming ;
Shao, Zhiming ;
Yang, Wentao ;
Zhou, Xiaoyan .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (10) :2935-2944
[18]   Imaging Features of Triple Negative Breast Cancer and the Effect of BRCA Mutations [J].
Karbasian, Niloofar ;
Sohrabi, Sahand ;
Omofoye, Toma S. ;
Le-Petross, Huong ;
Arun, Banu K. ;
Albarracin, Constance T. ;
Hess, Kenneth R. ;
Gutierrez-Barrera, Angelica M. ;
Whitman, Gary J. .
CURRENT PROBLEMS IN DIAGNOSTIC RADIOLOGY, 2021, 50 (03) :303-307
[19]   Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers [J].
Kuchenbaecker, Karoline B. ;
Hopper, John L. ;
Barnes, Daniel R. ;
Phillips, Kelly-Anne ;
Mooij, Thea M. ;
Roos-Blom, Marie-Jose ;
Jervis, Sarah ;
van Leeuwen, Flora E. ;
Milne, Roger L. ;
Andrieu, Nadine ;
Goldgar, David E. ;
Terry, Mary Beth ;
Rookus, Matti A. ;
Easton, Douglas F. ;
Antoniou, Antonis C. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (23) :2402-2416
[20]   Radiomics Study of Thyroid Ultrasound for Predicting BRAF Mutation in Papillary Thyroid Carcinoma: Preliminary Results [J].
Kwon, M. -r. ;
Shin, J. H. ;
Park, H. ;
Cho, H. ;
Hahn, S. Y. ;
Park, K. W. .
AMERICAN JOURNAL OF NEURORADIOLOGY, 2020, 41 (04) :700-705